Staffordshire pet pharmaceuticals firm Dechra saw revenues rise in its third quarter as the company continued to benefit from the buoyant pet critical care market.
The firm’s pharmaceuticals division grew revenues by 24 per cent in the third quarter compared to the same period last year. For the nine months to 31 March 2009 – which includes the full benefit of the company’s purchase of Denmark-based VetXX in 2007 – revenue was ahead of last year by 85 per cent.
The company said that since the launch of Vetoryl – a treatment for canine hyperadrenocorticism – US revenues to date from the product stand at £1.1 million. The company said it was confident it would continue to make good strategic progress throughout the the financial year.